Efficacy and Safety of Bevacizumab Combined with Chemotherapy as Second-line or Later-line Treatment in Advanced Nonsquamous Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2018.07.02
- Author:
Xuanxuan ZHENG
1
;
Huijuan WANG
1
;
Guowei ZHANG
1
;
Xiangtao YAN
1
;
Zhiyong MA
1
Author Information
1. Department of Respiratory Medicine, the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital,
Zhengzhou 450008, China.
- Publication Type:Journal Article
- Keywords:
Bevacizumab;
Brain metastases;
Chemotherapy;
Efficacy;
Lung neoplasms
- MeSH:
Aged;
Bevacizumab;
adverse effects;
therapeutic use;
Brain Neoplasms;
secondary;
Carcinoma, Non-Small-Cell Lung;
drug therapy;
pathology;
Disease-Free Survival;
Female;
Humans;
Lung Neoplasms;
drug therapy;
pathology;
Male;
Middle Aged;
Retrospective Studies;
Safety;
Treatment Outcome
- From:
Chinese Journal of Lung Cancer
2018;21(7):513-518
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Bevacizumab combined with platinum-based chemotherapy has been recommended as the first-line agent in advanced nonsquamous non-small cell lung cancer (NSCLC) without driven gene, but this regimen is not common in the second-line or later-line treatment of non-squamous NSCLC. The aim of this study is to investigate the efficacy and safety of bevacizumab combined with chemotherapy as second-line or later-line treatment in advanced non-squamous NSCLC.
METHODS:We retrospectively reviewed the clinical data of advanced nonsquamous NSCLC patients who were treated with bevacizumab after first-line treatment failure and they were hospitalized in the Affiliated Cancer Hospital of Zhengzhou University from January 2014 to June 2017, and Kaplan-Meier method, Log-rank test and Cox model were used for analysis.
RESULTS:A total of 62 patients were included in the analysis. The total objective response rate (ORR) was 32.2%, and the disease control rate (DCR) was 96.8%. The median progression-free survival (PFS) was 6.4 months (95%CI: 6.05-6.83), and the median overall survival (OS) was 20.4 months (95%CI: 12.98-27.76). In the subgroup analysis, there was no significant difference in median PFS between patients with brain metastases and those without brain metastases (6.2 months vs 6.4 months, P=0.052). Cycles of bevacizumab (>6 or ≤6 cycles) was an independent influencing factor of PFS (P=0.004). The most common adverse events were leukopenia, fatigue, nausea, thrombocytopenia and hypertension.
CONCLUSIONS:In the second-line or later-line treatment, bevacizumab combined with chemotherapy is an effective and safe regimen for advanced non-squamous NSCLC.
